Callio Therapeutics Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221 in Advanced HER2-Expressing Solid Tumors

Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for ...